RxDoctor Payments Data

David Johnson, MD

Internal Medicine · Little River, SCNPI 1790705796

Payments from drug & device makers

$660in general payments, 2019–2025

Across 30 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vasorum USA Inc.$267
  • Johnson & Johnson$101
  • AstraZeneca$65
  • GSK$52
  • Sunovion Pharmaceuticals Inc.$45
  • Amgen$40
  • plus $89 from 6 others

What the payments were for

  • Food & beverage$660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$660 in reported general payments places this provider in the 60th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$153,666
Medicare patients
486
Services billed
1,670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban115$101,560
JanuviaSitagliptin Phosphate79$72,340
JardianceEmpagliflozin61$62,524
OzempicSemaglutide30$47,813
XareltoRivaroxaban29$31,002
LinzessLinaclotide24$22,802
MounjaroTirzepatide20$21,968
Nurtec OdtRimegepant Sulfate14$14,224
FarxigaDapagliflozin Propanediol16$14,107
SymbicortBudesonide/Formoterol Fumarate11$7,196
Atorvastatin Calcium536$5,431
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$4,550
Duloxetine Hcl100$3,735
Losartan Potassium339$3,681
Ezetimibe145$3,399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$47,81330 claims
Johnson & JohnsonXarelto$101$31,00229 claims
AstraZenecaFarxiga, Symbicort$65$21,30327 claims
Sanofi-aventis U.S. LLCLantus$11$1,35715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Little River

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →